Skip to main content

ALGS

Stock
Health Care
Biotechnology

Performance overview

ALGS Price
Price Chart

Forward-looking statistics

Beta
0.89
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.

Company info

SectorHealth Care
IndustryBiotechnology
Employees75
Market cap$42.2M

Fundamentals

Enterprise value-$85.9M
Revenue$3.3M
Revenue per employee
Profit margin0.00%
Debt to equity6.76

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$17.47
Dividend per share
Revenue per share$0.48
Avg trading volume (30 day)$1M
Avg trading volume (10 day)$835K
Put-call ratio

Macro factor sensitivity

Growth-3.9
Credit+9.0
Liquidity-1.3
Inflation-5.8
Commodities-1.6
Interest Rates-3.6

Valuation

Dividend yield0.00%
PEG Ratio-0.66
Price to sales14.66
P/E Ratio-0.66
Enterprise Value to Revenue-26.27
Price to book0.41

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.80. This compares to loss of $5.50 per share a year ago.

Zacks Investment Research (May 6, 2025)
Aligos Therapeutics Raises $84M Via Equity At 7% Discount

Aligos Therapeutics Inc (NASDAQ: ALGS) has priced a previously announced underwritten public offering of 4.4 million shares at $19 per share, representing a discount of 7% from the last close price of $20.3 on Wednesday. The gross proceeds will be approximately $83.6 million.

Benzinga (July 1, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free